The use of Minimized Extracorporeal Circulation System has a Beneficial Effect on Hemostasis--A Randomized Clinical Study


  • Ulf Abdel-Rahman
  • Sven Martens
  • Petar Risteski
  • Feyzan Özaslan
  • Musawir Riaz
  • Anton Moritz
  • Gerhard Wimmer-Greinecker



Background. Conventional cardiopulmonary bypass (CPB) is associated with increased coagulation and fibrinolytic activity. A closed miniaturized bypass circuit (CorX) features a significantly reduced tubing set, an integrated pump, and an air removal system without a cardiotomy reservoir. In a prospective randomized trial, the effects on hemostasis were investigated while comparing CorX with conventional CPB in patients undergoing coronary artery bypass grafting.

Methods. Over a period of 1 year, 81 patients were randomly assigned either to the CorX system (n = 39, group A) or standard CPB system (n = 42, group B). Primary endpoints were platelet count, plasmin-antiplasmin complex (PAP), prothrombin fragments 1+2 (F1+F2), D-dimers, and fibrinogen. Secondary end-points were hematocrit, blood loss in the first 12 hours postoperatively, transfused packed red blood cells, and fresh frozen plasma in the first 24 hours postoperatively. In addition, we analyzed partial thromboplastin time, prothrombin time, and antithrombin III.

Results. After aortic declamping, PAP complex and prothrombin F1+F2 were significantly lower in group A than in group B. The difference in D-dimers between groups reached significance at 1 hour post-CPB. Hematocrit values at the end of CPB measured 26 ± 6% in group A versus 22 ± 4% in group B (P = .01). The rest of the observed parameters did not significantly differ between groups.

Conclusion. Postoperative blood loss was not reduced in the present study. However, the use of the CorX system leads to a significant suppression of activation of coagulation and fibrinolytic cascades compared to conventional CPB, suggesting that miniaturized extracorporeal circuits are a step forward toward reduced imbalance of hemostasis in cardiac surgery.


Abdel-Rahman U, Ozaslan F, Risteski PS, et al. 2005. Initial experience with a minimized extracorporeal bypass system: is there a clinical benefit? Ann Thorac Surg 80:238-43.nCenters for Disease Control and Prevention. 2003. Life expectancy at birth, at 65 years of age, and at 75 years of age, according to race and sex: United States, selected years 1900-2001. Table 27. (Accessed December 16, 2004, at S. 1996. Review on the multifactorial aspects of bioincompatibility in CPB. Perfusion 11:246-55.nEdmunds, LH. 2004. Cardiopulmonary bypass after 50 years. N Engl J Med 351;16:1603-6.nFolliguet TA, Villa E, Vandeneyden F, Laborde F. 2003. Coronary artery bypass graft with minimal extracorporeal circulation. Heart Surg Forum 6:297-301.nGibbon JH Jr. 1954. Application of a mechanical heart and lung apparatus to cardiac surgery. Minn Med 37:171-85.nChai PJ, Nassar R, Oakeley AE, et al. 2000. Soluble complement receptor-1 protects heart, lung, and cardiac myofilament function from cardiopulmonary bypass damage. Circulation 101:541-6.nFallen D, Komorowski B, Groh M. 2003. Perfusion-assisted beating heart CABG with a miniature bypass system is associated with improved outcomes compared to traditional CPB-supported CABG. Heart Surg Forum 6:207-8.nFromes Y, Gaillard D, Ponzio O, et al. 2002. Reduction of the inflammatory response following coronary bypass grafting with total minimal extracorporeal circulation. Eur J Cardiothorac Surg 22:527-33.nMueller XM, Jegger D, Augstburger M, Horisberger J, Godar G, von Segesser LK. 2002. A new concept of integrated cardiopulmonary bypass circuit. Eur J Cardiothorac Surg 21:840-6.nNaik SK, Knight A, Elliot M. 1991. A prospective randomized study of a modified technique of ultrafiltration during pediatric open-heart surgery. Circulation 84(Suppl III):422-31.nNashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. 1999. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 16:9-13.nZahler S, Massoudy P, Hartl H, Hahnel C, Meisner H, Becker BF. 1999. Acute cardiac inflammatory responses to postischemic reperfusion during cardiopulmonary bypass Cardiovasc Res 41:722-30.nWimmer-Greinecker G, Matheis G, Martens S, Oremek G, Abdel-Rahman U, Moritz A. 1999. Synthetic protein treated versus heparin coated cardiopulmonary bypass surfaces: similar results and minor bio chemical differences. Eur J Cardio-thorac Surg 16:211-17.nvon Segesser LK, Tozzi P, Mallbiabrrena I, Jegger D, Horisberger J, Corno A. 2003. Miniaturization in cardiopulmonary bypass. Perfusion 18:219-224.nWachtfogel YT, Kucich U, Hack CE, et al. 1993. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 106:1-9.nWestaby S. Organ dysfunction after cardiopulmonary bypass. 1987. A systemic inflammatory reaction initiated by the extracorporeal circuit. Intensive Care Med 13:89-95.nKirklin JK, Westaby S, Blackstone EH, Kirklin JW, Chenoweth DE, Pacifico AD. 1983. Complement and the damaging effects of cardiopulmonary bypass. J Thorac Cardiovasc Surg 86:845-57.nLuciani GB, Menon T, Vecchi B, et al. 2003. Modified ultrafiltration reduces morbidity after adult cardiac operations: a prospective, randomized clinical trial. Circulation 104(Suppl I):253-9.nMuehrcke DD, McCarthy PM, Kottke-Marchant K, et al. 1996. Biocompatibility of heparin-coated extracorporeal bypass circuits: a randomized masked clinical trial. J Thorac Cardiovasc Surg 112:472-83.nGourlary T. 2001. Biomaterial developement for cardiopulmonary bypass. Perfusion 16:380-391.nGu Y, van Oeveren W, Akkerman C, Boonstra P, Huyzen R, Wildevuur C. 1993. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 55:917-22.nHill GE, Alonso A, Thiele GM, Robbins RA. 1994. Glucocorticoids blunt neutrophil CD11b surface glycoprotein upregulation during cardiopulmonary bypass in humans. Anesth Analg 79:23.nHill GE, Alonso A, Spurzem JR, et al. 1995. Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovasc Surg 110:1658-62.nJansen NJ, van Oeveren W, Gu YJ, van Vliet MH, Eijsman L, Wildevuur CR. 1992. Endotoxin release and tumor necrosis factor formation during cardiopulmonary bypass. Ann Thorac Surg 54:744-8.nMatheis G. 2001. Leukocyte filtration in cardiac surgery: a review. Perfusion 16:361-70.nMou SS, Giroir BP, Molitor-Kirsch EA, et al. 2004. Fresh whole blood versus reconstituted blood for pump priming in heart surgery in infants. N Engl J Med 351:1635-44.nMurase M, Usui A, Tomita Y, et al. 1993. Nafamostat mesilate reduces blood loss during open heart surgery. Circulation 88(Suppl II):432-6.nScholz M, Simon A, Matheis G, et al. 2002. Leukocyte filtration fails to limit functional neutrophil activity during cardiac surgery. Inflamm Res 51:363-8.nProndzinsky R, Knüpfer A, Lappnow H, et al. 2005. Surgical trauma affects the proinflammatory status after cardiac surgery to a higher degree than cardiopulmonary bypass. J Thorac Cardiovasc Surg 129:760-6.nRemadi JP, Marticho P, Butoi I, et al. 2004. Clinical experience with the mini-extracorporeal circulation system: an evolution or a revolution? Ann Thorac Surg 77:2172-6.nVaislic C, Bical O, Farge C, et al. 2003. Totally minimized extracorporeal circulation: an important benefit for coronary artery bypass grafting in Jehovah's witnesses. Heart Surg Forum 6:307-10.n



How to Cite

Abdel-Rahman, U., Martens, S., Risteski, P., Özaslan, F., Riaz, M., Moritz, A., & Wimmer-Greinecker, G. (2006). The use of Minimized Extracorporeal Circulation System has a Beneficial Effect on Hemostasis--A Randomized Clinical Study. The Heart Surgery Forum, 9(1), E543-E548.